Bristol Myers Squibb y el uso de Sotyktu (deucravacitinib)
Bristol Myers Squibb anuncia la opinión positiva del CHMP para el uso de Sotyktu (deucravacitinib) una vez al día para
Leer másInstituto Español de Formadores en Salud
Bristol Myers Squibb anuncia la opinión positiva del CHMP para el uso de Sotyktu (deucravacitinib) una vez al día para
Leer másEl 64º Congreso y Exposición Anual de la Sociedad Americana de Hematología (ASH) tendrá lugar en Nueva Orleans (EE.UU), y
Leer másCookie | Duración | Descripción |
---|---|---|
cookielawinfo-checkbox-analytics | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics". |
cookielawinfo-checkbox-functional | 11 months | The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional". |
cookielawinfo-checkbox-necessary | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary". |
cookielawinfo-checkbox-others | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other. |
cookielawinfo-checkbox-performance | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance". |
viewed_cookie_policy | 11 months | The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data. |